The patient was a 75-year-old black male who presented to his primary care physician with abdominal pain, poor appetite, generalized weakness, and unintentional weight loss for three weeks. The physical exam yielded mild tenderness in the LLQ and RUQ without guarding or rebound tenderness. Significant laboratory values included an elevated WBC of 13,600 cells/mL; alkaline phosphatase, 144 IU/L; and total bilirubin 2.2 mg/dL.
Transabdominal ultrasound (US) identified a distended, thick-walled gallbladder, diffuse biliary tract dilatation, and a hepatic mass. Computed tomography and MRCP confirmed these findings and identified an ill-defined intraductal mass at the confluence of the hepatic ducts. A CA 19-9 level was markedly elevated at 761 U/mL. Biopsies from the biliary and hepatic masses, and a necrotic lymph node in the porta hepatis were histologically confirmed to be cholangiocarcinoma. The patient was transferred to a tertiary care center for palliative stent placement, as he was not a surgical candidate.
The patient presented with classic imaging findings of a perihilar cholangiocarcinoma. Transabdominal US showed diffuse intrahepatic biliary congestion, a small mass near the porta hepatis, and a dilated, thick-walled gall bladder (Figure 1). Recognizing a dilated or crowded biliary tree is a critical, though nonspecific, step in the workup of cholangiocarcinomas. A CT scan confirmed the presence of a hyperattenuating mass on arterial phase (Figure 2). MRCP confirmed a hypointense intraductal mass on STIR sequence, diffuse biliary congestion, and distended irregular gallbladder (Figures 3 and 4).
Perihilar cholangiocarcinoma (Type 4)
Patients with cholangiocarcinoma most often present with painless jaundice and other signs of biliary obstruction: scleral icterus, dark urine, clay-colored stools, or generalized pruritus. This occurs earlier if the tumor is located in the common bile duct or common hepatic duct. Constitutional symptoms and abdominal pain only occur in advanced disease. There may be a palpable non-tender gallbladder on physical exam. (1, 2)
Abnormally elevated laboratory values in cholangiocarcinomas include alkaline phosphatase, gamma-glutamyl transpeptidase, and direct bilirubin levels. The tumor markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) are frequently elevated as well. CA 19-9 is the most useful tumor marker in this illness as it is elevated in about 80% of cases and clinically linked to prognosis. A CA19-9 level > 129 U/L in the setting of a biliary mass is highly suggestive of cholangiocarcinoma. (3, 4)
Radiologic features and tumor classification
Transabdominal ultrasound (US) is often a starting point for patients presenting with RUQ pain or jaundice. It can identify dilation of the biliary tree, hepatic cysts, and some hepatic and biliary masses. Irregular US findings often result in additional imaging and cholangiography (ERCP, PTC, MRCP). Computed tomography (CT), especially multiphase, is useful for identifying and differentiating masses and lymphadenopathy. Positron emission tomography/CT (PET/CT) is useful in staging and identify metastasis in intrahepatic cholangiocarcinoma. However, PET/CT is less sensitive and specific in patients with extrahepatic disease or concomitant primary sclerosing cholangitis due to increased background uptake. Standard magnetic resonance imaging (MRI) is also sensitive in identifying masses and lymph nodes. MRI provides the added benefit of characterizing relevant changes in the surrounding connective tissue and liver parenchyma. MRCP is useful in mapping disease and strictures in the biliary tree. MRI--angiogram is critical for evaluating vascular involvement of the tumor. Endosonography is the most sensitive method for evaluating local lymph node invasion. In fact, endosonography-guided lymph node biopsies are required to histologically rule out lymph node metastasis. (1, 5, 6)
Cholangiocarcinomas are divided into intrahepatic, extrahepatic (perihilar), and distal extrahepatic cholangiocarcinoma. The AJCC defines perihilar cholangiocarcinoma (Klatskin tumors) as occurring from the right and left hepatic ducts to the common bile duct. Intrahepatic tumors occur starting in the secondary biliary radicles and distal extrahepatic cholangiocarcinomas arise from the common bile duct forward. (7, 8) The most commonly used classification system for perihilar cholangiocarcinomas specifically is the Bismuth-Corlette System. The tumor in this case was a type IV cholangiocarcinoma with multi-focal involvement extending from the confluence of the hepatic ducts to the common bile duct (Table 2).
It is also important for radiologists to have a cursory knowledge of the staging system and contraindications for surgery in order to communicate effectively with ordering physicians. In this case the patient was not a surgical candidate based on local metastasis and N2 lymph node involvement (Table 3).
Pathophysiology and histology
The exact cause of cholangiocarcinoma is unknown. However, risk factors include: ulcerative colitis associated primary sclerosing cholangitis, choledochal cysts, liver flukes (Clinorchis or Opisthorcis), Thorotrast, and familial syndromes (SBLA Syndrome and HNPCC). (2, 8, 9) The common theme is proinflammatory changes leading to epithelial dysplasia and carcinogenesis. (10) Cholangiocarcinoma has been linked to mutations in p53, BCL-2, and KRAS. However, recent advances in genetic research suggest a more complex genetic origin.
The vast majority of these tumors are adenocarcinoma arising from the biliary epithelium. However, a variety of rare cell types have also been discovered. These include squamous and mucinous cholangiocarcinoma. Cholangiocarcinoma may also be broken down by growth pattern: exophytic, infiltrating, polypoid, and mixed. Perihilar cholangiocarcinomas are most often infiltrating. They present as poorly differentiated desmoplastic adenocarcinomas with poor blood flow aggressively infiltrating the surrounding tissue. (9)
Perihilar cholangiocarcinomas are relatively rare gastrointestinal malignancies. They are most often detected after lymphatic metastasis or direct invasion of other organs. Patients with cholangiocarcinoma most often present with jaundice or other symptoms of cholestasis. However, they may present with vague constitutional symptoms. Cholangiocarcinomas are very aggressive and have poor prognoses. The most effective way to augment survival is early identification and surgical intervention. Thus, radiologists must remain vigilant for the radiologic stigmata of cholangiocarcinomas to facilitate early diagnosis and optimize patient outcomes.
(1.) Darwin PE, Espat, NJ. Medscape. Cholangiocarcinoma. http://emedicine.medscape.com/article/277393-overview?pa=0GOJKRCB%2Bru0JZbaf%2FxHCZT7%2F%2Bz85vfEsZVpXSEBX6F18wgK9YdQUJpch0iMpOrMX8MwC0EECwzp432Skuf9qw%3D%3D. Updated 9 August 2016. Accessed 26 July 2016.
(2.) Castano-Llano R. Hilar Cholangiocarcinoma (Klatskin tumor). Revista Colombiana de Gastroenterologia. 2011; 26 (2): 116-124.
(3.) Levy C, Lymp J, Angulo P, Gores GJ, Larusso N, Lindor KD. The value of serum CA 19-9 in predicting cholangiocarcinomas in patients with primary sclerosing cholangitis. Digestive Diseases in Science. 2005; 50:1734-1740. doi: 10.1007/s10620-005-2927-2928
(4.) Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. Journal of Gastrointestinal Oncology. 2012;3(2):105-119. doi:10.3978/j.issn.2078-6891.2011.021.
(5.) Han JK, Choi BI, Kim AY, An SK, Lee JW, Kim TK, Kim SW. Cholangiocaricinoma: pictorial essay of CT and cholangiographic findings. Radiographics. 2002; 22:1. doi:10.1148/radiographics.22.1.g02ja15173.
(6.) Sainani NI, Catalano OA, Holalkere NS, Zhu AX, Hahn PF, Sahani, DV. Cholangiocarcinoma: current and novel imaging techniques. Radiographics. 2008;28:5. doi:10.1148/rg.285075183.
(7.) Farges O, Fuks D, LeTreut YP, et al. AJCC 7th edition of TNM staging accurately discriminates outcomes of patients with resectable intrahepatic cholangiocarcinoma: by the AFC-IHCC-2009 study group. Cancer. 2010; 117:2170-2177. doi: 10.1002/cncr.25712
(8.) Blechacz B, Komuta M, Roskams T, Gores GJ. Clinical diagnosis and staging of cholangiocarcinoma. Nature Reviews Gastroenterology & Hepatology. 2011; 8(9):512-522. doi:10.1038/nrgastro.2011.131.
(9.) Lim JH, ParkCK. Pathology of cholangiocarcinoma. Abdominal Imaging. 2004; 29(5):540-547. doi:10.1007/s00261-004-0187-2
(10.) Blechacz B, Gores GJ. Cholangiocarcinoma: Advances in Pathogenesis, Diagnosis, and Treatment. Hepatology. 2008;48(1):308-321. doi:10.1002/hep.22310.
Brian J. Di Giacinto, BS, OMS IV; Ashley M. Bohn, BS, OMS IV; and Amit K. Sanghi, BS, DO
Prepared by Mr. Di Giacinto and Ms. Bohn while fourth-year medical students at Edward Via College of Osteopathic Medicine - Carolinas Campus, Spartanburg, SC, and completing clerkships at Orangeburg Regional Medical Center, Orangeburg, SC; and Dr. Sanghi while serving as Director of MRI Studies; Department of Radiology, Orangeburg Regional Medical Center, Orangeburg, SC.
Table 1. Imaging findings in perihilar cholangiocarcinoma (6) Transabdominal Ultrasound Biliary dilatation, Hepatic lobar atrophy, Biliary crowding, Mixed echogenicity mass with low blood flow on Doppler-US Computed Tomography Biliary dilatation, Irregular thickening of biliary tree, Hepatic lobe atrophy or encasement, Hypoattenuating (arterial/venous phase) or Hyperattenuating (delayed phase) lesion, Hepatic architecture distortion Magnetic Resonance Imaging Biliary dilatation, Irregular thickening of biliary tree, Hepatic lobe atrophy or encasement, Masses show: Hypo-Isointense signal (T1/STIR), Hyperintense signal (T2), or early peripheral and late diffuse enhancement on Fat-saturated T1 weighted imaging with IV contrast (*) US = Ultrasound; STIR = Short tau inversion recovery; IV = intravenous Table 2. Bismuth-Corlette perihilar cholangiocarcinoma classification system (1) Type I Involves common hepatic duct only Type II Involves confluence of the primary hepatic ducts Type IIIa Extends from the bifurcation up the right hepatic duct Type IIIb Extends from the bifurcation up the left hepatic duct Type IV Extends bilaterally from the bifurcation of the common hepatic duct or multifocal involvement Table 3: Contraindications to curative surgery (1) Medical Contraindications A. Medically Unft B. Liver Cirrhosis C. Portal Hypertension Tumor Contraindications A. Encasement of Portal Vein B. Hepatic Lobe Atrophy + Contralateral encasement of portal vein branch or involvement of secondary biliary radicles C. Bilateral involvement of secondary biliary radicles D. Metastasis: a. N2 Lymph Node Metastasis b. Local or Distant Metastasis (*) N2 = Distant regional node metastasis (Periaortic, pericaval, SMA, celiac)
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||RADIOLOGICAL CASE|
|Author:||Di Giacinto, Brian J.; Bohn, Ashley M.; Sanghi, Amit K.|
|Article Type:||Case study|
|Date:||Jun 1, 2018|
|Previous Article:||Nonketotic hyperglycemia-induced hemichorea-hemiballism.|
|Next Article:||Extraosseous multiple myeloma.|